CINXE.COM

<!DOCTYPE html> <html lang="en" dir="ltr"> <head>  <script async src="https://www.googletagmanager.com/gtag/js?id=G-P63WKM1TM1"></script> <script> window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-P63WKM1TM1'); </script>  <script type="text/javascript" > (function(m,e,t,r,i,k,a){m[i]=m[i]||function(){(m[i].a=m[i].a||[]).push(arguments)}; m[i].l=1*new Date(); for (var j = 0; j < document.scripts.length; j++) {if (document.scripts[j].src === r) { return; }} k=e.createElement(t),a=e.getElementsByTagName(t)[0],k.async=1,k.src=r,a.parentNode.insertBefore(k,a)}) (window, document, "script", "https://mc.yandex.ru/metrika/tag.js", "ym"); ym(55165297, "init", { clickmap:false, trackLinks:true, accurateTrackBounce:true, webvisor:false }); </script> <noscript><div><img src="https://mc.yandex.ru/watch/55165297" style="position:absolute; left:-9999px;" alt="" /></div></noscript>    <title>Search results for: solid lipid nanoparticles</title> <meta name="description" content="Search results for: solid lipid nanoparticles"> <meta name="keywords" content="solid lipid nanoparticles"> <meta name="viewport" content="width=device-width, initial-scale=1, minimum-scale=1, maximum-scale=1, user-scalable=no"> <meta charset="utf-8"> <link href="https://cdn.waset.org/favicon.ico" type="image/x-icon" rel="shortcut icon"> <link href="https://cdn.waset.org/static/plugins/bootstrap-4.2.1/css/bootstrap.min.css" rel="stylesheet"> <link href="https://cdn.waset.org/static/plugins/fontawesome/css/all.min.css" rel="stylesheet"> <link href="https://cdn.waset.org/static/css/site.css?v=150220211555" rel="stylesheet"> </head> <body> <header> <div class="container"> <nav class="navbar navbar-expand-lg navbar-light"> <a class="navbar-brand" href="https://waset.org"> <img src="https://cdn.waset.org/static/images/wasetc.png" alt="Open Science Research Excellence" title="Open Science Research Excellence" /> </a> <button class="d-block d-lg-none navbar-toggler ml-auto" type="button" data-toggle="collapse" data-target="#navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"> <span class="navbar-toggler-icon"></span> </button> <div class="w-100"> <div class="d-none d-lg-flex flex-row-reverse"> <form method="get" action="https://waset.org/search" class="form-inline my-2 my-lg-0"> <input class="form-control mr-sm-2" type="search" placeholder="Search Conferences" value="solid lipid nanoparticles" name="q" aria-label="Search"> <button class="btn btn-light my-2 my-sm-0" type="submit"><i class="fas fa-search"></i></button> </form> </div> <div class="collapse navbar-collapse mt-1" id="navbarMenu"> <ul class="navbar-nav ml-auto align-items-center" id="mainNavMenu"> <li class="nav-item"> <a class="nav-link" href="https://waset.org/conferences" title="Conferences in 2024/2025/2026">Conferences</a> </li> <li class="nav-item"> <a class="nav-link" href="https://waset.org/disciplines" title="Disciplines">Disciplines</a> </li> <li class="nav-item"> <a class="nav-link" href="https://waset.org/committees" rel="nofollow">Committees</a> </li> <li class="nav-item dropdown"> <a class="nav-link dropdown-toggle" href="#" id="navbarDropdownPublications" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false"> Publications </a> <div class="dropdown-menu" aria-labelledby="navbarDropdownPublications"> <a class="dropdown-item" href="https://publications.waset.org/abstracts">Abstracts</a> <a class="dropdown-item" href="https://publications.waset.org">Periodicals</a> <a class="dropdown-item" href="https://publications.waset.org/archive">Archive</a> </div> </li> <li class="nav-item"> <a class="nav-link" href="https://waset.org/page/support" title="Support">Support</a> </li> </ul> </div> </div> </nav> </div> </header> <main> <div class="container mt-4"> <div class="row"> <div class="col-md-9 mx-auto"> <form method="get" action="https://publications.waset.org/abstracts/search"> <div id="custom-search-input"> <div class="input-group"> <i class="fas fa-search"></i> <input type="text" class="search-query" name="q" placeholder="Author, Title, Abstract, Keywords" value="solid lipid nanoparticles"> <input type="submit" class="btn_search" value="Search"> </div> </div> </form> </div> </div> <div class="row mt-3"> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Commenced</strong> in January 2007</div> </div> </div> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Frequency:</strong> Monthly</div> </div> </div> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Edition:</strong> International</div> </div> </div> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Paper Count:</strong> 4169</div> </div> </div> </div> <h1 class="mt-3 mb-3 text-center" style="font-size:1.6rem;">Search results for: solid lipid nanoparticles</h1> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">4169</span> Lipid Nanoparticles for Spironolactone Delivery: Physicochemical Characteristics, Stability and Invitro Release</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=H.%20R.%20Kelidari">H. R. Kelidari</a>, <a href="https://publications.waset.org/abstracts/search?q=M.%20Saeedi"> M. Saeedi</a>, <a href="https://publications.waset.org/abstracts/search?q=J.%20Akbari"> J. Akbari</a>, <a href="https://publications.waset.org/abstracts/search?q=K.%20Morteza-Semnani"> K. Morteza-Semnani</a>, <a href="https://publications.waset.org/abstracts/search?q=H.%20Valizadeh"> H. Valizadeh </a> </p> <p class="card-text"><strong>Abstract:</strong></p> Spironolactoe (SP) a synthetic steroid diuretic is a poorly water-soluble drug with a low and variable oral bioavailability. Regarding to the good solubility of SP in lipid materials, SP loaded Solid lipid nanoparticles (SP-SLNs) and nanostructured lipid carrier (SP-SLNs) were thus prepared in this work for accelerating dissolution of this drug. The SP loaded NLC with stearic acid (SA) as solid lipid and different Oleic Acid (OA) as liquid lipid content and SLN without OA were prepared by probe ultrasonication method. With increasing the percentage of OA from 0 to 30 wt% in SLN/NLC, the average size and zeta potential of nanoparticles felled down and entrapment efficiency (EE %) rose dramatically. The obtained micrograph particles showed pronounced spherical shape. Differential Scanning Calorimeter (DSC) measurements indicated that the presence of OA reduced the melting temperature and melting enthalpy of solid lipid in NLC structure. The results reflected good long-term stability of the nanoparticles and the measurements show that the particle size remains lower in NLC compare to SLN formulations, 6 months after production. Dissolution of SP-SLN and SP-NLC was about 5.1 and 7.2 times faster than raw drugs in 120 min respectively. These results indicated that the SP loaded NLC containing 70:30 solid lipid to liquid lipid ratio is a suitable carrier of SP with improved drug EE and steady drug release properties. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=drug%20release" title="drug release">drug release</a>, <a href="https://publications.waset.org/abstracts/search?q=lipid%20nanoparticles" title=" lipid nanoparticles"> lipid nanoparticles</a>, <a href="https://publications.waset.org/abstracts/search?q=spironolactone" title=" spironolactone"> spironolactone</a>, <a href="https://publications.waset.org/abstracts/search?q=stability" title=" stability"> stability</a> </p> <a href="https://publications.waset.org/abstracts/30285/lipid-nanoparticles-for-spironolactone-delivery-physicochemical-characteristics-stability-and-invitro-release" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/30285.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">331</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">4168</span> Novel Solid Lipid Nanoparticles for Oral Delivery of Oxyresveratrol: Effect of the Formulation Parameters on the Physicochemical Properties and in vitro Release </h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Yaowaporn%20Sangsen">Yaowaporn Sangsen</a>, <a href="https://publications.waset.org/abstracts/search?q=Kittisak%20Likhitwitayawuid"> Kittisak Likhitwitayawuid</a>, <a href="https://publications.waset.org/abstracts/search?q=Boonchoo%20Sritularak"> Boonchoo Sritularak</a>, <a href="https://publications.waset.org/abstracts/search?q=Kamonthip%20Wiwattanawongsa"> Kamonthip Wiwattanawongsa</a>, <a href="https://publications.waset.org/abstracts/search?q=Ruedeekorn%20Wiwattanapatapee"> Ruedeekorn Wiwattanapatapee</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Novel solid lipid nanoparticles (SLNs) were developed to improve oral bioavailability of oxyresveratrol (OXY). The SLNs were prepared by a high speed homogenization technique, at an effective speed and time, using Compritol® 888 ATO (5% w/w) as the solid lipid. The appropriate weight proportions (0.3% w/w) of OXY affected the physicochemical properties of blank SLNs. The effects of surfactant types on the properties of the formulations such as particle size and entrapment efficacy were also investigated. Conclusively, Tween 80 combined with soy lecithin was the most appropriate surfactant to stabilize OXY-loaded SLNs. The mean particle size of the optimized formulation was 134.40 ± 0.57 nm. In vitro drug release study, the selected S2 formulation showed a retarded release profile for OXY with no initial burst release compared to OXY suspension in the simulated gastrointestinal fluids. Therefore, these SLNs could provide a suitable system to develop for the oral OXY delivery. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=solid%20lipid%20nanoparticles" title="solid lipid nanoparticles">solid lipid nanoparticles</a>, <a href="https://publications.waset.org/abstracts/search?q=physicochemical%20properties" title=" physicochemical properties"> physicochemical properties</a>, <a href="https://publications.waset.org/abstracts/search?q=in%20vitro%20drug%20release" title=" in vitro drug release"> in vitro drug release</a>, <a href="https://publications.waset.org/abstracts/search?q=oxyresveratrol" title=" oxyresveratrol"> oxyresveratrol</a> </p> <a href="https://publications.waset.org/abstracts/3625/novel-solid-lipid-nanoparticles-for-oral-delivery-of-oxyresveratrol-effect-of-the-formulation-parameters-on-the-physicochemical-properties-and-in-vitro-release" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/3625.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">397</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">4167</span> Famotidine Loaded Solid Lipid Nanoparticles (SLN) for Oral Delivery System</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Rachmat%20Mauludin">Rachmat Mauludin</a>, <a href="https://publications.waset.org/abstracts/search?q=Novita%20R.%20Kusuma"> Novita R. Kusuma</a>, <a href="https://publications.waset.org/abstracts/search?q=Diky%20Mudhakir"> Diky Mudhakir</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Famotidine (FMT) is one of used substances in the treatment of hiperacidity and peptic ulcer, administered orally and parenterally via intravenous injection. Oral administration, which is more favorable, has been reported to have many obstacles in the process of the treatment, includes decreasing the bioavailability of FMT. This research was aimed to prepare FMT in form of solid lipid nanoparticles (SLN) with size ranging between 100-200 nm. The research was carried out also by optimizing factors that may affect physical stability of SLN. Formulation of Famotidine SLN was carried out by optimizing factors, such as duration of homogenization and sonication, lipid concentration, stabilizer composition and stabilizer concentration. SLN physical stability was evaluated (particle size distribution) for 42 days in 3 diferent temperatures. Entrapment efficiency and drug loading was determined indirectly and directly. The morphology of SLN was visualized by transmission electron microscope (TEM). In vitro release study of FMT was conducted in 2 mediums, at pH of 1.2 and 7.4. Chemical stability of FMT was determined by quantifying the concentration of FMT within 42 days. Famotidin SLN consisted of GMS as lipid and poloxamer 188, lecithin, and polysorbate 80 as stabilizers. Homogenization and sonication was performed for 5 minutes and 10 minutes. Physyical stability of nanoparticles at 3 different temperatures was no significant difference. The best formula was physically stable until 42 days with mean particle size below 200 nm. Nanoparticles produced was able to entrap FMT until 86.6%. Evaluation by TEM showed that nanoparticles was spherical and solid. In medium pH of 1.2, FMT was released only 30% during 4 hour. On the other hand, within 4 hours SLN could release FMT completely in medium pH of 7.4. The FMT concentration in nanoparticles dispersion was maintained until 95% in 42 days (40oC, RH 75%). Famotidine SLN was able to be produced with mean particle size ranging between 100-200 nm and physically stable for 42 days. SLN could be loaded by 86,6% of FMT. Morphologically, obtained SLN was spheric and solid. During 4 hours in medium pH of 1.2 and 7.4, FMT was released until 30% and 100%, respectively. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=solid%20lipid%20nanoparticle%20%28SLN%29" title="solid lipid nanoparticle (SLN)">solid lipid nanoparticle (SLN)</a>, <a href="https://publications.waset.org/abstracts/search?q=famotidine%20%28FMT%29" title=" famotidine (FMT)"> famotidine (FMT)</a>, <a href="https://publications.waset.org/abstracts/search?q=physicochemical%20properties" title=" physicochemical properties"> physicochemical properties</a>, <a href="https://publications.waset.org/abstracts/search?q=release%20study" title=" release study"> release study</a> </p> <a href="https://publications.waset.org/abstracts/19816/famotidine-loaded-solid-lipid-nanoparticles-sln-for-oral-delivery-system" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/19816.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">360</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">4166</span> Topical Delivery of Griseofulvin via Lipid Nanoparticles</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Yann%20Jean%20Tan">Yann Jean Tan</a>, <a href="https://publications.waset.org/abstracts/search?q=Hui%20Meng%20Er"> Hui Meng Er</a>, <a href="https://publications.waset.org/abstracts/search?q=Choy%20Sin%20Lee"> Choy Sin Lee</a>, <a href="https://publications.waset.org/abstracts/search?q=Shew%20Fung%20Wong"> Shew Fung Wong</a>, <a href="https://publications.waset.org/abstracts/search?q=Wen%20Huei%20Lim"> Wen Huei Lim</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Griseofulvin is a long standing fungistatic agent against dermatophytosis. Nevertheless, it has several drawbacks such as poor and highly variable bio availability, long duration of treatment, systemic side effects and drug interactions. Targeted treatment for the superficial skin infection, dermatophytosis via topical route could be beneficial. Nevertheless, griseofulvin is only available in the form of oral preparation. Hence, it generates interest in developing a topical formulation for griseofulvin, by using lipid nano particle as the vehicle. Lipid nanoparticle is a submicron colloidal carrier with a core that is solid in nature (lipid). It has combined advantages of various traditional carriers and is a promising vehicle for topical delivery. The griseofulvin loaded lipid nano particles produced using high pressure homogenization method were characterized and investigated for its skin targeting effect in vitro. It has a mean particle size of 179.8±4.9 nm with polydispersity index of 0.306±0.011. Besides, it showed higher skin permeation and better skin targeting effect compared to the griseofulvin suspension. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=lipid%20nanoparticles" title="lipid nanoparticles">lipid nanoparticles</a>, <a href="https://publications.waset.org/abstracts/search?q=griseofulvin" title=" griseofulvin"> griseofulvin</a>, <a href="https://publications.waset.org/abstracts/search?q=topical" title=" topical"> topical</a>, <a href="https://publications.waset.org/abstracts/search?q=dermatophytosis" title=" dermatophytosis"> dermatophytosis</a> </p> <a href="https://publications.waset.org/abstracts/18028/topical-delivery-of-griseofulvin-via-lipid-nanoparticles" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/18028.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">458</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">4165</span> Nanopharmaceutical: A Comprehensive Appearance of Drug Delivery System</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Mahsa%20Fathollahzadeh">Mahsa Fathollahzadeh</a> </p> <p class="card-text"><strong>Abstract:</strong></p> The various nanoparticles employed in drug delivery applications include micelles, liposomes, solid lipid nanoparticles, polymeric nanoparticles, functionalized nanoparticles, nanocrystals, cyclodextrins, dendrimers, and nanotubes. Micelles, composed of amphiphilic block copolymers, can encapsulate hydrophobic molecules, allowing for targeted delivery. Liposomes, vesicular structures made up of phospholipids, can encapsulate both hydrophobic and hydrophilic molecules, providing a flexible platform for delivering therapeutic agents. Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) are designed to improve the stability and bioavailability of lipophilic drugs. Polymeric nanoparticles, such as poly(lactic-co-glycolic acid) (PLGA), are biodegradable and can be engineered to release drugs in a controlled manner. Functionalized nanoparticles, coated with targeting ligands or antibodies, can specifically target diseased cells or tissues. Nanocrystals, engineered to have specific surface properties, can enhance the solubility and bioavailability of poorly soluble drugs. Cyclodextrins, doughnut-shaped molecules with hydrophobic cavities, can be complex with hydrophobic molecules, allowing for improved solubility and bioavailability. Dendrimers, branched polymers with a central core, can be designed to deliver multiple therapeutic agents simultaneously. Nanotubes and metallic nanoparticles, such as gold nanoparticles, offer real-time tracking capabilities and can be used to detect biomolecular interactions. The use of these nanoparticles has revolutionized the field of drug delivery, enabling targeted and controlled release of therapeutic agents, reduced toxicity, and improved patient outcomes. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=nanotechnology" title="nanotechnology">nanotechnology</a>, <a href="https://publications.waset.org/abstracts/search?q=nanopharmaceuticals" title=" nanopharmaceuticals"> nanopharmaceuticals</a>, <a href="https://publications.waset.org/abstracts/search?q=drug-delivery" title=" drug-delivery"> drug-delivery</a>, <a href="https://publications.waset.org/abstracts/search?q=proteins" title=" proteins"> proteins</a>, <a href="https://publications.waset.org/abstracts/search?q=ligands" title=" ligands"> ligands</a>, <a href="https://publications.waset.org/abstracts/search?q=nanoparticles" title=" nanoparticles"> nanoparticles</a>, <a href="https://publications.waset.org/abstracts/search?q=chemistry" title=" chemistry"> chemistry</a> </p> <a href="https://publications.waset.org/abstracts/186065/nanopharmaceutical-a-comprehensive-appearance-of-drug-delivery-system" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/186065.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">51</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">4164</span> Development of capsaicin-loaded nanostructured lipid carriers for topical application</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Kwanputtha%20Arunprasert">Kwanputtha Arunprasert</a>, <a href="https://publications.waset.org/abstracts/search?q=Chaiyakarn%20Pornpitchanarong"> Chaiyakarn Pornpitchanarong</a>, <a href="https://publications.waset.org/abstracts/search?q=Praneet%20Opanasopit"> Praneet Opanasopit</a>, <a href="https://publications.waset.org/abstracts/search?q="></a>, <a href="https://publications.waset.org/abstracts/search?q=Prasopchai%20Patrojanasophon">Prasopchai Patrojanasophon</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Capsaicin, a recently FDA-approved drug for the topical treatment of neuropathic pain, is associated with several side effects like burning sensation and erythema leading to severe skin irritation and poor patient compliance. These unwanted side effects are due to the rapid penetration of capsaicin into the epidermis and low permeation to the dermis layer. The purpose of this study was to develop nanostructured lipid carriers (NLCs) that entrapped capsaicin for reducing dermal irritation. Solid lipid (glyceryl monostearate (GM), cetyl palmitate (CP), cetyl alcohol (COH), stearic acid (SA), and stearyl alcohol (SOH)) and surfactant (Tween®80, Tween®20, and Span®20) were varied to obtained optimal capsaicin-loaded NLCs. The formulation using CP as solid lipid and Tween®80 as a surfactant (F2) demonstrated the smallest size, excellent colloidal stability, and narrow range distribution of the particles as being analyzed using Zetasizer. The obtained capsaicin-loaded NLCs were then characterized by entrapment efficiency (EE) and loading capacity (LC). The release characteristics followed Higuchi kinetics, and the prolonged capsaicin release may result in the reduction in skin irritation. These results could demonstrate the potentials of capsaicinloaded lipid-based nanoparticles for topical drug delivery. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=capsaicin" title="capsaicin">capsaicin</a>, <a href="https://publications.waset.org/abstracts/search?q=lipid-based%20nanoparticles" title=" lipid-based nanoparticles"> lipid-based nanoparticles</a>, <a href="https://publications.waset.org/abstracts/search?q=nanostructured%20lipid%20carriers" title=" nanostructured lipid carriers"> nanostructured lipid carriers</a>, <a href="https://publications.waset.org/abstracts/search?q=topical%20drug%20delivery%20system" title=" topical drug delivery system"> topical drug delivery system</a> </p> <a href="https://publications.waset.org/abstracts/179761/development-of-capsaicin-loaded-nanostructured-lipid-carriers-for-topical-application" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/179761.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">76</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">4163</span> Delivery of Doxorubicin to Glioblastoma Multiforme Using Solid Lipid Nanoparticles with Surface Aprotinin and Melanotransferrin Antibody for Enhanced Chemotherapy</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Yung-Chih%20Kuo">Yung-Chih Kuo</a>, <a href="https://publications.waset.org/abstracts/search?q=I-Hsuan%20Lee"> I-Hsuan Lee</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Solid lipid nanoparticles (SLNs) conjugated with aprotinin (Apr) and melanotransferrin antibody (Anti-MTf) were used to carry doxorubicin (Dox) across the blood–brain barrier (BBB) for glioblastoma multiforme (GBM) chemotherapy. Dox-entrapped SLNs with grafted Apr and Anti-MTf (Apr-Anti-MTf-Dox-SLNs) were applied to a cultured monolayer comprising human brain-microvascular endothelial cells (HBMECs) with regulation of human astrocyte (HAs) and to a proliferated colony of U87MG cells. Based on the average particle diameter, zeta potential, entrapping efficiency of Dox, and grafting efficiency of Apr and Anti-MTf, we found that 40% (w/w) 1,2-dipalmitoyl-sn-glycero-3-phosphocholine in lipids were appropriate for fabricating Apr-Anti-MTf-Dox-SLNs. In addition, Apr-Anti-MTf-Dox-SLNs could prevent Dox from fast dissolution and did not induce a serious cytotoxicity to HBMECs and HAs when compared with free Dox. Moreover, the treatments with Apr-Anti-MTf-Dox-SLNs enhanced the ability of Dox to infuse the BBB and to inhibit the growth of GBM. The current Apr-Anti-MTf-Dox-SLNs can be a promising pharmacotherapeutic preparation to penetrate the BBB for malignant brain tumor treatment. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=solid%20lipid%20nanoparticle" title="solid lipid nanoparticle">solid lipid nanoparticle</a>, <a href="https://publications.waset.org/abstracts/search?q=glioblastoma%20multiforme" title=" glioblastoma multiforme"> glioblastoma multiforme</a>, <a href="https://publications.waset.org/abstracts/search?q=blood%E2%80%93brain%20barrier" title=" blood–brain barrier"> blood–brain barrier</a>, <a href="https://publications.waset.org/abstracts/search?q=doxorubicin" title=" doxorubicin"> doxorubicin</a> </p> <a href="https://publications.waset.org/abstracts/38612/delivery-of-doxorubicin-to-glioblastoma-multiforme-using-solid-lipid-nanoparticles-with-surface-aprotinin-and-melanotransferrin-antibody-for-enhanced-chemotherapy" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/38612.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">362</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">4162</span> Preparation and Characterization of Diclofenac Sodium Loaded Solid Lipid Nanoparticle</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Oktavia%20Eka%20Puspita">Oktavia Eka Puspita</a> </p> <p class="card-text"><strong>Abstract:</strong></p> The possibility of using Solid Lipid Nanoparticles (SLN) for topical use is an interesting feature concerning this system has occlusive properties on the skin surface therefore enhance the penetration of drugs through the stratum corneum by increased hydration. This advantage can be used to enhance the drug penetration of topical delivery such as Diclofenac sodium for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. The purpose of this study was focused on the preparation and physical characterization of Diclofenac sodium loaded SLN (D-SLN). D loaded SLN were prepared by hot homogenization followed by ultrasonication technique. Since the occlusion factor of SLN is related to its particle size the formulation of D-SLN in present study two formulations different in its surfactant contents were prepared to investigate the difference of the particle size resulted. Surfactants selected for preparation of formulation A (FA) were lecithin soya and Tween 80 whereas formulation B (FB) were lecithin soya, Tween 80, and Sodium Lauryl Sulphate. D-SLN were characterized for particle size and distribution, polydispersity index (PI), zeta potential using Beckman-Coulter Delsa™ Nano. Overall, the particle size obtained from FA was larger than FB. FA has 90% of the particles were above 1000 nm, while FB has 90% were below 100 nm. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=solid%20lipid%20nanoparticles" title="solid lipid nanoparticles">solid lipid nanoparticles</a>, <a href="https://publications.waset.org/abstracts/search?q=hot%20homogenization%20technique" title=" hot homogenization technique"> hot homogenization technique</a>, <a href="https://publications.waset.org/abstracts/search?q=particle%20size%20analysis" title=" particle size analysis"> particle size analysis</a>, <a href="https://publications.waset.org/abstracts/search?q=topical%20administration" title=" topical administration"> topical administration</a> </p> <a href="https://publications.waset.org/abstracts/16904/preparation-and-characterization-of-diclofenac-sodium-loaded-solid-lipid-nanoparticle" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/16904.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">500</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">4161</span> Development and Characterization of Topical 5-Fluorouracil Solid Lipid Nanoparticles for the Effective Treatment of Non-Melanoma Skin Cancer</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Sudhir%20Kumar">Sudhir Kumar</a>, <a href="https://publications.waset.org/abstracts/search?q=V.%20R.%20Sinha"> V. R. Sinha</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background: The topical and systemic toxicity associated with present nonmelanoma skin cancer (NMSC) treatment therapy using 5-Fluorouracil (5-FU) make it necessary to develop a novel delivery system having lesser toxicity and better control over drug release. Solid lipid nanoparticles offer many advantages like: controlled and localized release of entrapped actives, nontoxicity, and better tolerance. Aim:-To investigate safety and efficacy of 5-FU loaded solid lipid nanoparticles as a topical delivery system for the treatment of nonmelanoma skin cancer. Method: Topical solid lipid nanoparticles of 5-FU were prepared using Compritol 888 ATO (Glyceryl behenate) as lipid component and pluronic F68 (Poloxamer 188), Tween 80 (Polysorbate 80), Tyloxapol (4-(1,1,3,3-Tetramethylbutyl) phenol polymer with formaldehyde and oxirane) as surfactants. The SLNs were prepared with emulsification method. Different formulation parameters viz. type and ratio of surfactant, ratio of lipid and ratio of surfactant:lipid were investigated on particle size and drug entrapment efficiency. Results: Characterization of SLNs like–Transmission Electron Microscopy (TEM), Differential Scannig calorimetry (DSC), Fourier transform infrared spectroscopy (FTIR), Particle size determination, Polydispersity index, Entrapment efficiency, Drug loading, ex vivo skin permeation and skin retention studies, skin irritation and histopathology studies were performed. TEM results showed that shape of SLNs was spherical with size range 200-500nm. Higher encapsulation efficiency was obtained for batches having higher concentration of surfactant and lipid. It was found maximum 64.3% for SLN-6 batch with size of 400.1±9.22 nm and PDI 0.221±0.031. Optimized SLN batches and marketed 5-FU cream were compared for flux across rat skin and skin drug retention. The lesser flux and higher skin retention was obtained for SLN formulation in comparison to topical 5-FU cream, which ensures less systemic toxicity and better control of drug release across skin. Chronic skin irritation studies lacks serious erythema or inflammation and histopathology studies showed no significant change in physiology of epidermal layers of rat skin. So, these studies suggest that the optimized SLN formulation is efficient then marketed cream and safer for long term NMSC treatment regimens. Conclusion: Topical and systemic toxicity associated with long-term use of 5-FU, in the treatment of NMSC, can be minimized with its controlled release with significant drug retention with minimal flux across skin. The study may provide a better alternate for effective NMSC treatment. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=5-FU" title="5-FU">5-FU</a>, <a href="https://publications.waset.org/abstracts/search?q=topical%20formulation" title=" topical formulation"> topical formulation</a>, <a href="https://publications.waset.org/abstracts/search?q=solid%20lipid%20nanoparticles" title=" solid lipid nanoparticles"> solid lipid nanoparticles</a>, <a href="https://publications.waset.org/abstracts/search?q=non%20melanoma%20skin%20cancer" title=" non melanoma skin cancer"> non melanoma skin cancer</a> </p> <a href="https://publications.waset.org/abstracts/20727/development-and-characterization-of-topical-5-fluorouracil-solid-lipid-nanoparticles-for-the-effective-treatment-of-non-melanoma-skin-cancer" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/20727.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">517</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">4160</span> Formulation and Invivo Evaluation of Salmeterol Xinafoate Loaded MDI for Asthma Using Response Surface Methodology</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Paresh%20Patel">Paresh Patel</a>, <a href="https://publications.waset.org/abstracts/search?q=Priya%20Patel"> Priya Patel</a>, <a href="https://publications.waset.org/abstracts/search?q=Vaidehi%20Sorathiya"> Vaidehi Sorathiya</a>, <a href="https://publications.waset.org/abstracts/search?q=Navin%20Sheth"> Navin Sheth</a> </p> <p class="card-text"><strong>Abstract:</strong></p> The aim of present work was to fabricate Salmeterol Xinafoate (SX) metered dose inhaler (MDI) for asthma and to evaluate the SX loaded solid lipid nanoparticles (SLNs) for pulmonary delivery. Solid lipid nanoparticles can be used to deliver particles to the lungs via MDI. A modified solvent emulsification diffusion technique was used to prepare Salmeterol Xinafoate loaded solid lipid nanoparticles by using compritol 888 ATO as lipid, tween 80 as surfactant, D-mannitol as cryoprotecting agent and L-leucine was used to improve aerosolization behaviour. Box-Behnken design was applied with 17 runs. 3-D surface response plots and contour plots were drawn and optimized formulation was selected based on minimum particle size and maximum % EE. % yield, in vitro diffusion study, scanning electron microscopy, X-ray diffraction, DSC, FTIR also characterized. Particle size, zeta potential analyzed by Zetatrac particle size analyzer and aerodynamic properties was carried out by cascade impactor. Pre convulsion time was examined for control group, treatment group and compare with marketed group. MDI was evaluated for leakage test, flammability test, spray test and content per puff. By experimental design, particle size and % EE found to be in range between 119-337 nm and 62.04-76.77% by solvent emulsification diffusion technique. Morphologically, particles have spherical shape and uniform distribution. DSC & FTIR study showed that no interaction between drug and excipients. Zeta potential shows good stability of SLNs. % respirable fraction found to be 52.78% indicating reach to the deep part of lung such as alveoli. Animal study showed that fabricated MDI protect the lungs against histamine induced bronchospasm in guinea pigs. MDI showed sphericity of particle in spray pattern, 96.34% content per puff and non-flammable. SLNs prepared by Solvent emulsification diffusion technique provide desirable size for deposition into the alveoli. This delivery platform opens up a wide range of treatment application of pulmonary disease like asthma via solid lipid nanoparticles. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=salmeterol%20xinafoate" title="salmeterol xinafoate">salmeterol xinafoate</a>, <a href="https://publications.waset.org/abstracts/search?q=solid%20lipid%20nanoparticles" title=" solid lipid nanoparticles"> solid lipid nanoparticles</a>, <a href="https://publications.waset.org/abstracts/search?q=box-behnken%20design" title=" box-behnken design"> box-behnken design</a>, <a href="https://publications.waset.org/abstracts/search?q=solvent%20emulsification%20diffusion%20technique" title=" solvent emulsification diffusion technique"> solvent emulsification diffusion technique</a>, <a href="https://publications.waset.org/abstracts/search?q=pulmonary%20delivery" title=" pulmonary delivery"> pulmonary delivery</a> </p> <a href="https://publications.waset.org/abstracts/34847/formulation-and-invivo-evaluation-of-salmeterol-xinafoate-loaded-mdi-for-asthma-using-response-surface-methodology" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/34847.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">451</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">4159</span> Preparation and in vivo Assessment of Nystatin-Loaded Solid Lipid Nanoparticles for Topical Delivery against Cutaneous Candidiasis</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Rawia%20M.%20Khalil">Rawia M. Khalil</a>, <a href="https://publications.waset.org/abstracts/search?q=Ahmed%20A.%20Abd%20El%20Rahman"> Ahmed A. Abd El Rahman</a>, <a href="https://publications.waset.org/abstracts/search?q=Mahfouz%20A.%20Kassem"> Mahfouz A. Kassem</a>, <a href="https://publications.waset.org/abstracts/search?q=Mohamed%20S.%20El%20Ridi"> Mohamed S. El Ridi</a>, <a href="https://publications.waset.org/abstracts/search?q=Mona%20M.%20Abou%20Samra"> Mona M. Abou Samra</a>, <a href="https://publications.waset.org/abstracts/search?q=Ghada%20E.%20A.%20Awad"> Ghada E. A. Awad</a>, <a href="https://publications.waset.org/abstracts/search?q=Soheir%20S.%20Mansy"> Soheir S. Mansy</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Solid lipid nanoparticles (SLNs) have gained great attention for the topical treatment of skin associated fungal infection as they facilitate the skin penetration of loaded drugs. Our work deals with the preparation of nystatin loaded solid lipid nanoparticles (NystSLNs) using the hot homogenization and ultrasonication method. The prepared NystSLNs were characterized in terms of entrapment efficiency, particle size, zeta potential, transmission electron microscopy, differential scanning calorimetry, rheological behavior and in vitro drug release. A stability study for 6 months was performed. A microbiological study was conducted in male rats infected with Candida albicans, by counting the colonies and examining the histopathological changes induced on the skin of infected rats. The results showed that SLNs dispersions are spherical in shape with particle size ranging from 83.26±11.33 to 955.04±1.09 nm. The entrapment efficiencies are ranging from 19.73±1.21 to 72.46±0.66% with zeta potential ranging from -18.9 to -38.8 mV and shear-thinning rheological Behavior. The stability studies done for 6 months showed that nystatin (Nyst) is a good candidate for topical SLN formulations. A least number of colony forming unit/ ml (cfu/ml) was recorded for the selected NystSLN compared to the drug solution and the commercial Nystatin® cream present in the market. It can be fulfilled from this work that SLNs provide a good skin targeting effect and may represent promising carrier for topical delivery of Nyst offering the sustained release and maintaining the localized effect, resulting in an effective treatment of cutaneous fungal infection. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=candida%20infections" title="candida infections">candida infections</a>, <a href="https://publications.waset.org/abstracts/search?q=hot%20homogenization" title=" hot homogenization"> hot homogenization</a>, <a href="https://publications.waset.org/abstracts/search?q=nystatin" title=" nystatin"> nystatin</a>, <a href="https://publications.waset.org/abstracts/search?q=solid%20lipid%20nanoparticles" title=" solid lipid nanoparticles"> solid lipid nanoparticles</a>, <a href="https://publications.waset.org/abstracts/search?q=stability" title=" stability"> stability</a>, <a href="https://publications.waset.org/abstracts/search?q=topical%20delivery" title=" topical delivery"> topical delivery</a> </p> <a href="https://publications.waset.org/abstracts/3539/preparation-and-in-vivo-assessment-of-nystatin-loaded-solid-lipid-nanoparticles-for-topical-delivery-against-cutaneous-candidiasis" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/3539.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">393</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">4158</span> Formulation and Ex Vivo Evaluation of Solid Lipid Nanoparticles Based Hydrogel for Intranasal Drug Delivery</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Pramod%20Jagtap">Pramod Jagtap</a>, <a href="https://publications.waset.org/abstracts/search?q=Kisan%20Jadhav"> Kisan Jadhav</a>, <a href="https://publications.waset.org/abstracts/search?q=Neha%20Dand"> Neha Dand</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Risperidone (RISP) is an antipsychotic agent and has low water solubility and nontargeted delivery results in numerous side effects. Hence, an attempt was made to develop SLNs hydrogel for intranasal delivery of RISP to achieve maximum bioavailability and reduction of side effects. RISP loaded SLNs composed of 1.65% (w/v) lipid mass were produced by high shear homogenization (HSH) coupled ultrasound (US) method using glyceryl monostearate (GMS) or Imwitor 900K (solid lipid). The particles were loaded with 0.2% (w/v) of the RISP & surface-tailored with a 2.02% (w/v) non-ionic surfactant Tween® 80. Optimization was done using 32 factorial design using Design Expert® software. The prepared SLNs dispersion incorporated into Polycarbophil AA1 hydrogel (0.5% w/v). The final gel formulation was evaluated for entrapment efficiency, particle size, rheological properties, X ray diffraction, in vitro diffusion, ex vivo permeation using sheep nasal mucosa and histopathological studies for nasocilliary toxicity. The entrapment efficiency of optimized SLNs was found to be 76 ± 2 %, polydispersity index <0.3., particle size 278 ± 5 nm. This optimized batch was incorporated into hydrogel. The pH was found to be 6.4 ± 0.14. The rheological behaviour of hydrogel formulation revealed no thixotropic behaviour. In histopathology study, there was no nasocilliary toxicity observed in nasal mucosa after ex vivo permeation. X-ray diffraction data shows drug was in amorphous form. Ex vivo permeation study shows controlled release profile of drug. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=ex%20vivo" title="ex vivo">ex vivo</a>, <a href="https://publications.waset.org/abstracts/search?q=particle%20size" title=" particle size"> particle size</a>, <a href="https://publications.waset.org/abstracts/search?q=risperidone" title=" risperidone"> risperidone</a>, <a href="https://publications.waset.org/abstracts/search?q=solid%20lipid%20nanoparticles" title=" solid lipid nanoparticles"> solid lipid nanoparticles</a> </p> <a href="https://publications.waset.org/abstracts/20704/formulation-and-ex-vivo-evaluation-of-solid-lipid-nanoparticles-based-hydrogel-for-intranasal-drug-delivery" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/20704.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">419</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">4157</span> Bioavailability Enhancement of Ficus religiosa Extract by Solid Lipid Nanoparticles</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Sanjay%20Singh">Sanjay Singh</a>, <a href="https://publications.waset.org/abstracts/search?q=Karunanithi%20Priyanka"> Karunanithi Priyanka</a>, <a href="https://publications.waset.org/abstracts/search?q=Ramoji%20Kosuru"> Ramoji Kosuru</a>, <a href="https://publications.waset.org/abstracts/search?q=Raju%20Prasad%20Sharma"> Raju Prasad Sharma</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Herbal drugs are well known for their mixed pharmacological activities with the benefit of no harmful side effects. The use of herbal drugs is limited because of their higher dose requirement, frequent drug administration, poor bioavailability of phytochemicals and delayed onset of action. Ficus religiosa, a potent anti-oxidant plant useful in the treatment of diabetes and cancer was selected for the study. Solid lipid nanoparticles (SLN) of Ficus religiosa extract was developed for the enhancement in oral bioavailability of stigmasterol and β-sitosterol-d-glucoside, principal components present in the extract. Hot homogenization followed by ultrasonication method was used to develop extract loaded SLN. Developed extract loaded SLN were characterized for particle size, PDI, zeta potential, entrapment efficiency, in vitro drug release and kinetics, fourier transform infra-red spectroscopy, differential scanning calorimetry, powder X-ray diffractrometry and stability studies. Entrapment efficiency of optimized extract loaded SLN was found to be 68.46 % (56.13 % of stigmasterol and 12.33 % of β-sitosteryl-d-glucoside, respectively). RP HPLC method development was done for simultaneous estimation of stigmasterol and β-sitosterol-d-glucoside in Ficus religiosa extract in rat plasma. Bioavailability studies were carried out for extract in suspension form and optimized extract loaded SLN. AUC of stigmasterol and β-sitosterol-d-glucoside were increased by 6.7-folds by 9.2-folds, respectively in rats treated with extract loaded SLN compared to extract suspension. Also, Cmax of stigmasterol and β-sitosterol-d-glucoside were increased by 4.3-folds by 3.9-folds, respectively in rats treated with extract loaded SLN compared to extract suspension. Mean residence times (MRT) for stigmasterol were found to be 12.3 ± 0.67 hours from extract and 7.4 ± 2.1 hours from SLN and for β-sitosterol-d-glucoside, 10.49 ± 2.9 hours from extract and 6.4 ± 0.3 hours from SLN. Hence, it was concluded that SLN enhanced the bioavailability and reduced the MRT of stigmasterol and β-sitosterol-d-glucoside in Ficus religiosa extract which in turn may lead to reduction in dose of Ficus religiosa extract, prolonged duration of action and also enhanced therapeutic efficacy. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=Ficus%20religiosa" title="Ficus religiosa">Ficus religiosa</a>, <a href="https://publications.waset.org/abstracts/search?q=phytosterolins" title=" phytosterolins"> phytosterolins</a>, <a href="https://publications.waset.org/abstracts/search?q=bioavailability" title=" bioavailability"> bioavailability</a>, <a href="https://publications.waset.org/abstracts/search?q=solid%20lipid%20nanoparticles" title=" solid lipid nanoparticles"> solid lipid nanoparticles</a>, <a href="https://publications.waset.org/abstracts/search?q=stigmasterol%20and%20%CE%B2-sitosteryl-d-glucoside" title=" stigmasterol and β-sitosteryl-d-glucoside"> stigmasterol and β-sitosteryl-d-glucoside</a> </p> <a href="https://publications.waset.org/abstracts/17390/bioavailability-enhancement-of-ficus-religiosa-extract-by-solid-lipid-nanoparticles" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/17390.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">473</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">4156</span> Ph-Triggered Cationic Solid Lipid Nanoparticles Mitigated Colitis in Mice</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Muhammad%20Naeem">Muhammad Naeem</a>, <a href="https://publications.waset.org/abstracts/search?q=Juho%20Lee"> Juho Lee</a>, <a href="https://publications.waset.org/abstracts/search?q=Jin-Wook%20%20Yoo"> Jin-Wook Yoo</a> </p> <p class="card-text"><strong>Abstract:</strong></p> In this study, we hypothesized that prolonged gastrointestinal transit at the inflamed colon conferred by a pH-triggered mucoadhesive smart nanoparticulate drug delivery system aids in achieving selective and sustained levels of the drug within the inflamed colon for the treatment of ulcerative colitis. We developed budesonide-loaded pH-sensitive charge-reversal solid lipid nanoparticles (SLNs) using a hot homogenization method. Polyetylenimine (PEI) was used to render SLNs cationic (PEI-SLNs). Eudragit S100 (ES) was coated on PEI-SLNs for pH-trigger charge-reversal SLNs (ES-PEI-SLNs). Therapeutic potential of the prepared SNLs formulation was evaluated in ulcerative colitis in mice. The transmission electron microscopy, zeta size and zeta potential data showed the successful formation of SLNs formulations. SLNs and PEI-SLNs showed burst drug release in acidic pH condition mimicking stomach and early small intestine environment which limiting their application as oral delivery systems. However, ES-PEI-SLNs prevented a burst drug release in acidic pH conditions and showed sustained release at a colonic pH. Most importantly, the surface charge of ES-PEI-SLNs switched from negative to positive in colonic conditions by pH-triggered removal of ES coating and accumulated selectively in inflamed colon. Furthermore, a charge reversal ES-PEI-SLNs showed a superior mitigation of dextran sulfate sodium (DSS)-induced acute colitis in mice as compared to SLNs and PEI-SLNs treated groups. Moreover, histopathological analysis of distal colon sections stained with hematoxylin/eosin and E-cadherin immunostaining revealed attenuated inflammation in an ES-PEI-SLNs-treated group. We also found that ES-PEI-SLNs markedly reduced the myeloperoxidase level and expression of TNF-alpha in colon tissue. Our results suggest that the pH-triggered charge reversal SLNs presented in this study would be a promising approach for ulcerative colitis therapy. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=solid%20lipid%20nanoparticles" title="solid lipid nanoparticles">solid lipid nanoparticles</a>, <a href="https://publications.waset.org/abstracts/search?q=stimuli-triggered%20charge-reversal" title=" stimuli-triggered charge-reversal"> stimuli-triggered charge-reversal</a>, <a href="https://publications.waset.org/abstracts/search?q=ulcerative%20colitis" title=" ulcerative colitis"> ulcerative colitis</a>, <a href="https://publications.waset.org/abstracts/search?q=methacrylate%20copolymer" title=" methacrylate copolymer"> methacrylate copolymer</a>, <a href="https://publications.waset.org/abstracts/search?q=budesonide" title=" budesonide"> budesonide</a> </p> <a href="https://publications.waset.org/abstracts/66887/ph-triggered-cationic-solid-lipid-nanoparticles-mitigated-colitis-in-mice" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/66887.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">248</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">4155</span> Controlled Drug Delivery System for Delivery of Poor Water Soluble Drugs</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Raj%20Kumar">Raj Kumar</a>, <a href="https://publications.waset.org/abstracts/search?q=Prem%20Felix%20Siril"> Prem Felix Siril</a> </p> <p class="card-text"><strong>Abstract:</strong></p> The poor aqueous solubility of many pharmaceutical drugs and potential drug candidates is a big challenge in drug development. Nanoformulation of such candidates is one of the major solutions for the delivery of such drugs. We initially developed the evaporation assisted solvent-antisolvent interaction (EASAI) method. EASAI method is use full to prepared nanoparticles of poor water soluble drugs with spherical morphology and particles size below 100 nm. However, to further improve the effect formulation to reduce number of dose and side effect it is important to control the delivery of drugs. However, many drug delivery systems are available. Among the many nano-drug carrier systems, solid lipid nanoparticles (SLNs) have many advantages over the others such as high biocompatibility, stability, non-toxicity and ability to achieve controlled release of drugs and drug targeting. SLNs can be administered through all existing routes due to high biocompatibility of lipids. SLNs are usually composed of lipid, surfactant and drug were encapsulated in lipid matrix. A number of non-steroidal anti-inflammatory drugs (NSAIDs) have poor bioavailability resulting from their poor aqueous solubility. In the present work, SLNs loaded with NSAIDs such as Nabumetone (NBT), Ketoprofen (KP) and Ibuprofen (IBP) were successfully prepared using different lipids and surfactants. We studied and optimized experimental parameters using a number of lipids, surfactants and NSAIDs. The effect of different experimental parameters such as lipid to surfactant ratio, volume of water, temperature, drug concentration and sonication time on the particles size of SLNs during the preparation using hot-melt sonication was studied. It was found that particles size was directly proportional to drug concentration and inversely proportional to surfactant concentration, volume of water added and temperature of water. SLNs prepared at optimized condition were characterized thoroughly by using different techniques such as dynamic light scattering (DLS), field emission scanning electron microscopy (FESEM), transmission electron microscopy (TEM), atomic force microscopy (AFM), X-ray diffraction (XRD) and differential scanning calorimetry and Fourier transform infrared spectroscopy (FTIR). We successfully prepared the SLN of below 220 nm using different lipids and surfactants combination. The drugs KP, NBT and IBP showed 74%, 69% and 53% percentage of entrapment efficiency with drug loading of 2%, 7% and 6% respectively in SLNs of Campul GMS 50K and Gelucire 50/13. In-vitro drug release profile of drug loaded SLNs is shown that nearly 100% of drug was release in 6 h. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=nanoparticles" title="nanoparticles">nanoparticles</a>, <a href="https://publications.waset.org/abstracts/search?q=delivery" title=" delivery"> delivery</a>, <a href="https://publications.waset.org/abstracts/search?q=solid%20lipid%20nanoparticles" title=" solid lipid nanoparticles"> solid lipid nanoparticles</a>, <a href="https://publications.waset.org/abstracts/search?q=hot-melt%20sonication" title=" hot-melt sonication"> hot-melt sonication</a>, <a href="https://publications.waset.org/abstracts/search?q=poor%20water%20soluble%20drugs" title=" poor water soluble drugs"> poor water soluble drugs</a>, <a href="https://publications.waset.org/abstracts/search?q=solubility" title=" solubility"> solubility</a>, <a href="https://publications.waset.org/abstracts/search?q=bioavailability" title=" bioavailability"> bioavailability</a> </p> <a href="https://publications.waset.org/abstracts/46151/controlled-drug-delivery-system-for-delivery-of-poor-water-soluble-drugs" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/46151.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">312</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">4154</span> Solid Lipid Nanoparticles of Levamisole Hydrochloride</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Surendra%20Agrawal">Surendra Agrawal</a>, <a href="https://publications.waset.org/abstracts/search?q=Pravina%20Gurjar"> Pravina Gurjar</a>, <a href="https://publications.waset.org/abstracts/search?q=Supriya%20Bhide"> Supriya Bhide</a>, <a href="https://publications.waset.org/abstracts/search?q=Ram%20Gaud"> Ram Gaud</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Levamisole hydrochloride is a prominent anticancer drug in the treatment of colon cancer but resulted in toxic effects due poor bioavailability and poor cellular uptake by tumor cells. Levamisole is an unstable drug. Incorporation of this molecule in solid lipids may minimize their exposure to the aqueous environment and partly immobilize the drug molecules within the lipid matrix-both of which may protect the encapsulated drugs against degradation. The objectives of the study were to enhance bioavailability by sustaining drug release and to reduce the toxicities associated with the therapy. Solubility of the drug was determined in different lipids to select the components of Solid Lipid Nanoparticles (SLN). Pseudoternary phase diagrams were created using aqueous titration method. Formulations were subjected to particle size and stability evaluation to select the final test formulations which were characterized for average particle size, zeta potential, and in-vitro drug release and percentage transmittance to optimize the final formulation. SLN of Levamisole hydrochloride was prepared by Nanoprecipitation method. Glyceryl behenate (Compritol 888 ATO) was used as core comprising of Tween 80 as surfactant and Lecithin as co-surfactant in (1:1) ratio. Entrapment efficiency (EE) was found to be 45.89%. Particle size was found in the range of 100-600 nm. Zeta potential of the formulation was -17.0 mV revealing the stability of the product. In-vitro release study showed that 66 % drug released in 24 hours in pH 7.2 which represent that formulation can give controlled action at the intestinal environment. In pH 5.0 it showed 64% release indicating that it can even release drug in acidic environment of tumor cells. In conclusion, results revealed SLN to be a promising approach to sustain the drug release so as to increase bioavailability and cellular uptake of the drug with reduction in toxic effects as dose has been reduced with controlled delivery. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=SLN" title="SLN">SLN</a>, <a href="https://publications.waset.org/abstracts/search?q=nanoparticulate%20delivery%20of%20levamisole" title=" nanoparticulate delivery of levamisole"> nanoparticulate delivery of levamisole</a>, <a href="https://publications.waset.org/abstracts/search?q=pharmacy" title=" pharmacy"> pharmacy</a>, <a href="https://publications.waset.org/abstracts/search?q=pharmaceutical%20sciences" title=" pharmaceutical sciences"> pharmaceutical sciences</a> </p> <a href="https://publications.waset.org/abstracts/4063/solid-lipid-nanoparticles-of-levamisole-hydrochloride" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/4063.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">431</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">4153</span> Anonymous Gel-Fluid Transition of Solid Supported Lipids</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Asma%20Poursoroush">Asma Poursoroush</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Solid-supported lipid bilayers are often used as a simple model for studies of biological membranes. The presence of a solid substrate that interacts attractively with lipid head-groups is expected to affect the phase behavior of the supported bilayer. Molecular dynamics simulations of a coarse-grained model are thus performed to investigate the phase behavior of supported one-component lipid bilayer membranes. Our results show that the attraction of the lipid head groups to the substrate leads to a phase behavior that is different from that of a free standing lipid bilayer. In particular, we found that the phase behaviors of the two leaflets are decoupled in the presence of a substrate. The proximal leaflet undergoes a clear gel-to-fluid phase transition at a temperature lower than that of a free standing bilayer, and that decreases with increasing strength of the substrate-lipid attraction. The distal leaflet, however, undergoes a change from a homogeneous liquid phase at high temperatures to a heterogeneous state consisting of small liquid and gel domains, with the average size of the gel domains that increases with decreasing temperature. While the chain order parameter of the proximal leaflet clearly shows a gel-fluid phase transition, the chain order parameter of the distal leaflet does not exhibit a clear phase transition. The decoupling in the phase behavior of the two leaflets is due to a non-symmteric lipid distribution in the two leaflets resulting from the presence of the substrate. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=membrane" title="membrane">membrane</a>, <a href="https://publications.waset.org/abstracts/search?q=substrate" title=" substrate"> substrate</a>, <a href="https://publications.waset.org/abstracts/search?q=molecular%20dynamics" title=" molecular dynamics"> molecular dynamics</a>, <a href="https://publications.waset.org/abstracts/search?q=simulation" title=" simulation"> simulation</a> </p> <a href="https://publications.waset.org/abstracts/78473/anonymous-gel-fluid-transition-of-solid-supported-lipids" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/78473.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">195</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">4152</span> Lipid-Chitosan Hybrid Nanoparticles for Controlled Delivery of Cisplatin</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Muhammad%20Muzamil%20Khan">Muhammad Muzamil Khan</a>, <a href="https://publications.waset.org/abstracts/search?q=Asadullah%20Madni"> Asadullah Madni</a>, <a href="https://publications.waset.org/abstracts/search?q=Nina%20Filipczek"> Nina Filipczek</a>, <a href="https://publications.waset.org/abstracts/search?q=Jiayi%20Pan"> Jiayi Pan</a>, <a href="https://publications.waset.org/abstracts/search?q=Nayab%20Tahir"> Nayab Tahir</a>, <a href="https://publications.waset.org/abstracts/search?q=Hassan%20Shah"> Hassan Shah</a>, <a href="https://publications.waset.org/abstracts/search?q=Vladimir%20Torchilin"> Vladimir Torchilin</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Lipid-polymer hybrid nanoparticles (LPHNP) are delivery systems for controlled drug delivery at tumor sites. The superior biocompatible properties of lipid and structural advantages of polymer can be obtained via this system for controlled drug delivery. In the present study, cisplatin-loaded lipid-chitosan hybrid nanoparticles were formulated by the single step ionic gelation method based on ionic interaction of positively charged chitosan and negatively charged lipid. Formulations with various chitosan to lipid ratio were investigated to obtain the optimal particle size, encapsulation efficiency, and controlled release pattern. Transmission electron microscope and dynamic light scattering analysis demonstrated a size range of 181-245 nm and a zeta potential range of 20-30 mV. Compatibility among the components and the stability of formulation were demonstrated with FTIR analysis and thermal studies, respectively. The therapeutic efficacy and cellular interaction of cisplatin-loaded LPHNP were investigated using in vitro cell-based assays in A2780/ADR ovarian carcinoma cell line. Additionally, the cisplatin loaded LPHNP exhibited a low toxicity profile in rats. The in-vivo pharmacokinetics study also proved a controlled delivery of cisplatin with enhanced mean residual time and half-life. Our studies suggested that the cisplatin-loaded LPHNP being a promising platform for controlled delivery of cisplatin in cancer therapy. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=cisplatin" title="cisplatin">cisplatin</a>, <a href="https://publications.waset.org/abstracts/search?q=lipid-polymer%20hybrid%20nanoparticle" title=" lipid-polymer hybrid nanoparticle"> lipid-polymer hybrid nanoparticle</a>, <a href="https://publications.waset.org/abstracts/search?q=chitosan" title=" chitosan"> chitosan</a>, <a href="https://publications.waset.org/abstracts/search?q=in%20vitro%20cell%20line%20study" title=" in vitro cell line study"> in vitro cell line study</a> </p> <a href="https://publications.waset.org/abstracts/108442/lipid-chitosan-hybrid-nanoparticles-for-controlled-delivery-of-cisplatin" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/108442.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">130</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">4151</span> Inhalable Lipid-Coated-Chitosan Nano-Embedded Microdroplets of an Antifungal Drug for Deep Lung Delivery</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Ranjot%20Kaur">Ranjot Kaur</a>, <a href="https://publications.waset.org/abstracts/search?q=Om%20P.%20Katare"> Om P. Katare</a>, <a href="https://publications.waset.org/abstracts/search?q=Anupama%20Sharma"> Anupama Sharma</a>, <a href="https://publications.waset.org/abstracts/search?q=Sarah%20R.%20Dennison"> Sarah R. Dennison</a>, <a href="https://publications.waset.org/abstracts/search?q=Kamalinder%20K.%20Singh"> Kamalinder K. Singh</a>, <a href="https://publications.waset.org/abstracts/search?q=Bhupinder%20Singh"> Bhupinder Singh</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Respiratory microbial infections being among the top leading cause of death worldwide are difficult to treat as the microbes reside deep inside the airways, where only a small fraction of drug can access after traditional oral or parenteral routes. As a result, high doses of drugs are required to maintain drug levels above minimum inhibitory concentrations (MIC) at the infection site, unfortunately leading to severe systemic side-effects. Therefore, delivering antimicrobials directly to the respiratory tract provides an attractive way out in such situations. In this context, current study embarks on the systematic development of lung lia pid-modified chitosan nanoparticles for inhalation of voriconazole. Following the principles of quality by design, the chitosan nanoparticles were prepared by ionic gelation method and further coated with major lung lipid by precipitation method. The factor screening studies were performed by fractional factorial design, followed by optimization of the nanoparticles by Box-Behnken Design. The optimized formulation has a particle size range of 170-180nm, PDI 0.3-0.4, zeta potential 14-17, entrapment efficiency 45-50% and drug loading of 3-5%. The presence of a lipid coating was confirmed by FESEM, FTIR, and X-RD. Furthermore, the nanoparticles were found to be safe upto 40µg/ml on A549 and Calu-3 cell lines. The quantitative and qualitative uptake studies also revealed the uptake of nanoparticles in lung epithelial cells. Moreover, the data from Spraytec and next-generation impactor studies confirmed the deposition of nanoparticles in lower airways. Also, the interaction of nanoparticles with DPPC monolayers signifies its biocompatibility with lungs. Overall, the study describes the methodology and potential of lipid-coated chitosan nanoparticles in futuristic inhalation nanomedicine for the management of pulmonary aspergillosis. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=dipalmitoylphosphatidylcholine" title="dipalmitoylphosphatidylcholine">dipalmitoylphosphatidylcholine</a>, <a href="https://publications.waset.org/abstracts/search?q=nebulization" title=" nebulization"> nebulization</a>, <a href="https://publications.waset.org/abstracts/search?q=DPPC%20monolayers" title=" DPPC monolayers"> DPPC monolayers</a>, <a href="https://publications.waset.org/abstracts/search?q=quality-by-design" title=" quality-by-design"> quality-by-design</a> </p> <a href="https://publications.waset.org/abstracts/103730/inhalable-lipid-coated-chitosan-nano-embedded-microdroplets-of-an-antifungal-drug-for-deep-lung-delivery" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/103730.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">143</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">4150</span> Biocompatible Chitosan Nanoparticles as an Efficient Delivery Vehicle for Mycobacterium Tuberculosis Lipids to Induce Potent Cytokines and Antibody Response through Activation of γδ T-Cells in Mice</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Ishani%20Das">Ishani Das</a>, <a href="https://publications.waset.org/abstracts/search?q=Avinash%20Padhi"> Avinash Padhi</a>, <a href="https://publications.waset.org/abstracts/search?q=Sitabja%20Mukherjee"> Sitabja Mukherjee</a>, <a href="https://publications.waset.org/abstracts/search?q=Santosh%20Kar"> Santosh Kar</a>, <a href="https://publications.waset.org/abstracts/search?q=Avinash%20Sonawane"> Avinash Sonawane</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Activation of cell mediated and humoral immune responses to Mycobacterium tuberculosis (Mtb) are critical for protection. Herein, we show that mice immunized with Mtb lipid bound chitosan nanoparticles(NPs) induce secretion of prominent Th1 and Th2 cytokines in lymph node and spleen cells, and also induced significantly higher levels of IgG, IgG1, IgG2 and IgM in comparison to control mice measured by ELISA. Furthermore, significantly enhanced γδ-T cell activation was observed in lymph node cells isolated from mice immunized with Mtb lipid coated chitosan-NPs as compared to mice immunized with chitosan-NPs alone or Mtb lipid liposomes through flow cytometric analysis. Also, it was observed that in comparison to CD8+ cells, significantly higher CD4+ cells were present in both the lymph node and spleen cells isolated from mice immunized with Mtb lipid coated chitosan NP. In conclusion, this study represents a promising new strategy for efficient delivery of Mtb lipids using chitosan NPs to trigger enhanced cell mediated and antibody response against Mtb lipids. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=antibody%20response" title="antibody response">antibody response</a>, <a href="https://publications.waset.org/abstracts/search?q=chitosan%20nanoparticles" title=" chitosan nanoparticles"> chitosan nanoparticles</a>, <a href="https://publications.waset.org/abstracts/search?q=cytokines" title=" cytokines"> cytokines</a>, <a href="https://publications.waset.org/abstracts/search?q=mycobacterium%20tuberculosis%20lipids" title=" mycobacterium tuberculosis lipids"> mycobacterium tuberculosis lipids</a> </p> <a href="https://publications.waset.org/abstracts/55795/biocompatible-chitosan-nanoparticles-as-an-efficient-delivery-vehicle-for-mycobacterium-tuberculosis-lipids-to-induce-potent-cytokines-and-antibody-response-through-activation-of-ghd-t-cells-in-mice" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/55795.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">280</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">4149</span> Surface Modified Core–Shell Type Lipid–Polymer Hybrid Nanoparticles of Trans-Resveratrol, an Anticancer Agent, for Long Circulation and Improved Efficacy against MCF-7 Cells</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=M.%20R.%20Vijayakumar">M. R. Vijayakumar</a>, <a href="https://publications.waset.org/abstracts/search?q=K.%20Priyanka"> K. Priyanka</a>, <a href="https://publications.waset.org/abstracts/search?q=Ramoji%20Kosuru"> Ramoji Kosuru</a>, <a href="https://publications.waset.org/abstracts/search?q=Lakshmi"> Lakshmi</a>, <a href="https://publications.waset.org/abstracts/search?q=Sanjay%20Singh"> Sanjay Singh</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Trans resveratrol (RES) is a non-ﬂavonoid poly-phenolic compound proved for its therapeutic and preventive effect against various types of cancer. However, the practical application of RES in cancer treatment is limited because of its higher dose (up to 7.5 g/day in humans), low biological half life, rapid metabolism and faster elimination in mammals. PEGylated core-shell type lipid polymer hybrid nanoparticles are the novel drug delivery systems for long circulation and improved anti cancer effect of its therapeutic payloads. Therefore, the main objective of this study is to extend the biological half life (long circulation) and improve the therapeutic efficacy of RES through core shell type of nanoparticles. D-α-tocopheryl polyethylene glycol 1000 succinate (vitamin E TPGS), a novel surfactant is applied for the preparation of PEGylated lipid polymer hybrid nanoparticles. The prepared nanoparticles were evaluated by various state of the art techniques such as dynamic light scattering (DLS) technique for particle size and zeta potential, TEM for shape, differential scanning calorimetry (DSC) for interaction analysis and XRD for crystalline changes of drug. Entrapment efficiency and invitro drug release were determined by ultracentrifugation method and dialysis bag method, respectively. Cancer cell viability studies were performed by MTT assay, respectively. Pharmacokinetic studies after i.v administration were performed in sprague dawley rats. The prepared NPs were found to be spherical in shape with smooth surfaces. Particle size and zeta potential of prepared NPs were found to be in the range of 179.2±7.45 to 266.8±9.61 nm and -0.63 to -48.35 mV, respectively. DSC revealed absence of potential interaction. XRD study revealed presence of amorphous form in nanoparticles. Entrapment efficiency was found to be 83.7 % and drug release was found to be in controlled manner. MTT assay showed low MEC and pharmacokinetic studies showed higher AUC of nanoformulaition than its pristine drug. All these studies revealed that the RES loaded PEG modified core-shell type lipid polymer hybrid nanoparticles can be an alternative tool for chemopreventive and therapeutic application of RES in cancer. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=trans%20resveratrol" title="trans resveratrol">trans resveratrol</a>, <a href="https://publications.waset.org/abstracts/search?q=cancer%20nanotechnology" title=" cancer nanotechnology"> cancer nanotechnology</a>, <a href="https://publications.waset.org/abstracts/search?q=long%20circulating%20nanoparticles" title=" long circulating nanoparticles"> long circulating nanoparticles</a>, <a href="https://publications.waset.org/abstracts/search?q=bioavailability%20enhancement" title=" bioavailability enhancement"> bioavailability enhancement</a>, <a href="https://publications.waset.org/abstracts/search?q=core%20shell%20nanoparticles" title=" core shell nanoparticles"> core shell nanoparticles</a>, <a href="https://publications.waset.org/abstracts/search?q=lipid%20polymer%20hybrid%20nanoparticles" title=" lipid polymer hybrid nanoparticles"> lipid polymer hybrid nanoparticles</a> </p> <a href="https://publications.waset.org/abstracts/17395/surface-modified-core-shell-type-lipid-polymer-hybrid-nanoparticles-of-trans-resveratrol-an-anticancer-agent-for-long-circulation-and-improved-efficacy-against-mcf-7-cells" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/17395.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">472</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">4148</span> Formulation of Famotidine Solid Lipid Nanoparticles (SLN): Preparation, Evaluation and Release Study</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Rachmat%20Mauludin">Rachmat Mauludin</a>, <a href="https://publications.waset.org/abstracts/search?q=Nurmazidah"> Nurmazidah</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background and purpose: Famotidine is an H2 receptor blocker. Absorption orally is rapid enough, but famotidine can be degraded by stomach acid causing dose reduction until 35.8% after 50 minutes. This drug also undergoes first-pass metabolism which reduced its bio availability only until 40-50%. To overcome these problems, Solid Lipid Nano particles (SLNs) as alternative delivery systems can be formulated. SLNs is a lipid-based drug delivery technology with 50-1000 nm particle size, where the drug incorporated into the bio compatible lipids and the lipid particles are stabilized using appropriate stabilizers. When the particle size is 200 nm or below, lipid containing famotidine can be absorbed through the lymphatic vessels to the subclavian vein, so first-pass metabolism can be avoided. Method: Famotidine SLNs with various compositions of stabilizer was prepared using a high-speed homogenization and sonication method. Then, the particle size distribution, zeta potential, entrapment efficiency, particle morphology and in vitro release profiles were evaluated. Optimization of sonication time also carried out. Result: Particle size of SLN by Particle Size Analyzer was in range 114.6 up to 455.267 nm. Ultrasonicated SLNs within 5 minutes generated smaller particle size than SLNs which was ultrasonicated for 10 and 15 minutes. Entrapment efficiency of SLNs were 74.17 up to 79.45%. Particle morphology of the SLNs was spherical and distributed individually. Release study of Famotidine revealed that in acid medium, 28.89 up to 80.55% of famotidine could be released after 2 hours. Nevertheless in basic medium, famotidine was released 40.5 up to 86.88% in the same period. Conclusion: The best formula was SLNs which stabilized by 4% Poloxamer 188 and 1 % Span 20, that had particle size 114.6 nm in diameter, 77.14% famotidine entrapped, and the particle morphology was spherical and distributed individually. SLNs with the best drug release profile was SLNs which stabilized by 4% Eudragit L 100-55 and 1% Tween 80 which had released 36.34 % in pH 1.2 solution, and 74.13% in pH 7.4 solution after 2 hours. The optimum sonication time was 5 minutes. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=famotodine" title="famotodine">famotodine</a>, <a href="https://publications.waset.org/abstracts/search?q=SLN" title=" SLN"> SLN</a>, <a href="https://publications.waset.org/abstracts/search?q=high%20speed%20homogenization" title=" high speed homogenization"> high speed homogenization</a>, <a href="https://publications.waset.org/abstracts/search?q=particle%20size" title=" particle size"> particle size</a>, <a href="https://publications.waset.org/abstracts/search?q=release%20study" title=" release study"> release study</a> </p> <a href="https://publications.waset.org/abstracts/20331/formulation-of-famotidine-solid-lipid-nanoparticles-sln-preparation-evaluation-and-release-study" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/20331.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">860</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">4147</span> Cationic Solid Lipid Nanoparticles Conjugated with Anti-Melantransferrin and Apolipoprotein E for Delivering Doxorubicin to U87MG Cells</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Yung-Chih%20Kuo">Yung-Chih Kuo</a>, <a href="https://publications.waset.org/abstracts/search?q=Yung-I%20Lou"> Yung-I Lou</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Cationic solid lipid nanoparticles (CSLNs) with anti-melanotransferrin (AMT) and apolipoprotein E (ApoE) were used to carry antimitotic doxorubicin (Dox) across the blood–brain barrier (BBB) for glioblastoma multiforme (GBM) treatment. Dox-loaded CSLNs were prepared in microemulsion, grafted covalently with AMT and ApoE, and applied to human brain microvascular endothelial cells (HBMECs), human astrocytes, and U87MG cells. Experimental results revealed that an increase in the weight percentage of stearyl amine (SA) from 0% to 20% increased the size of AMT-ApoE-Dox-CSLNs. In addition, an increase in the stirring rate from 150 rpm to 450 rpm decreased the size of AMT-ApoE-Dox-CSLNs. An increase in the weight percentage of SA from 0% to 20% enhanced the zeta potential of AMT-ApoE-Dox-CSLNs. Moreover, an increase in the stirring rate from 150 rpm to 450 rpm reduced the zeta potential of AMT-ApoE-Dox-CSLNs. AMT-ApoE-Dox-CSLNs exhibited a spheroid-like geometry, a minor irregular boundary deviating from spheroid, and a somewhat distorted surface with a few zigzags and sharp angles. The encapsulation efficiency of Dox in CSLNs decreased with increasing weight percentage of Dox and the order in the encapsulation efficiency of Dox was 10% SA > 20% SA > 0% SA. However, the reverse order was true for the release rate of Dox, suggesting that AMT-ApoE-Dox-CSLNs containing 10% SA had better-sustained release characteristics. An increase in the concentration of AMT from 2.5 to 7.5 μg/mL slightly decreased the grafting efficiency of AMT and an increase in that from 7.5 to 10 μg/mL significantly decreased the grafting efficiency. Furthermore, an increase in the concentration of ApoE from 2.5 to 5 μg/mL slightly reduced the grafting efficiency of ApoE and an increase in that from 5 to 10 μg/mL significantly reduced the grafting efficiency. Also, AMT-ApoE-Dox-CSLNs at 10 μg/mL of ApoE could slightly reduce the transendothelial electrical resistance (TEER) and increase the permeability of propidium iodide (PI). An incorporation of 10 μg/mL of ApoE could reduce the TEER and increase the permeability of PI. AMT-ApoE-Dox-CSLNs at 10 μg/mL of AMT and 5-10 μg/mL of ApoE could significantly enhance the permeability of Dox across the BBB. AMT-ApoE-Dox-CSLNs did not induce serious cytotoxicity to HBMECs. The viability of HBMECs was in the following order: AMT-ApoE-Dox-CSLNs = AMT-Dox-CSLNs = Dox-CSLNs > Dox. The order in the efficacy of inhibiting U87MG cells was AMT-ApoE-Dox-CSLNs > AMT-Dox-CSLNs > Dox-CSLNs > Dox. A surface modification of AMT and ApoE could promote the delivery of AMT-ApoE-Dox-CSLNs to cross the BBB via melanotransferrin and low density lipoprotein receptor. Thus, AMT-ApoE-Dox-CSLNs have appropriate physicochemical properties and can be a potential colloidal delivery system for brain tumor chemotherapy. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=anti-melanotransferrin" title="anti-melanotransferrin">anti-melanotransferrin</a>, <a href="https://publications.waset.org/abstracts/search?q=apolipoprotein%20E" title=" apolipoprotein E"> apolipoprotein E</a>, <a href="https://publications.waset.org/abstracts/search?q=cationic%20catanionic%20solid%20lipid%20nanoparticle" title=" cationic catanionic solid lipid nanoparticle"> cationic catanionic solid lipid nanoparticle</a>, <a href="https://publications.waset.org/abstracts/search?q=doxorubicin" title=" doxorubicin"> doxorubicin</a>, <a href="https://publications.waset.org/abstracts/search?q=U87MG%20cells" title=" U87MG cells "> U87MG cells </a> </p> <a href="https://publications.waset.org/abstracts/69377/cationic-solid-lipid-nanoparticles-conjugated-with-anti-melantransferrin-and-apolipoprotein-e-for-delivering-doxorubicin-to-u87mg-cells" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/69377.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">284</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">4146</span> Effect of Wheat Germ Agglutinin- and Lactoferrin-Grafted Catanionic Solid Lipid Nanoparticles on Targeting Delivery of Etoposide to Glioblastoma Multiforme</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Yung-Chih%20Kuo">Yung-Chih Kuo</a>, <a href="https://publications.waset.org/abstracts/search?q=I-Hsin%20Wang"> I-Hsin Wang</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Catanionic solid lipid nanoparticles (CASLNs) with surface wheat germ agglutinin (WGA) and lactoferrin (Lf) were formulated for entrapping and releasing etoposide (ETP), crossing the blood–brain barrier (BBB), and inhibiting the growth of glioblastoma multiforme (GBM). Microemulsified ETP-CASLNs were modified with WGA and Lf for permeating a cultured monolayer of human brain-microvascular endothelial cells (HBMECs) regulated by human astrocytes and for treating malignant U87MG cells. Experimental evidence revealed that an increase in the concentration of catanionic surfactant from 5 μM to 7.5 μM reduced the particle size. When the concentration of catanionic surfactant increased from 7.5 μM to 12.5 μM, the particle size increased, yielding a minimal diameter of WGA-Lf-ETP-CASLNs at 7.5 μM of catanionic surfactant. An increase in the weight percentage of BW from 25% to 75% enlarged WGA-Lf-ETP-CASLNs. In addition, an increase in the concentration of catanionic surfactant from 5 to 15 μM increased the absolute value of zeta potential of WGA-Lf-ETP-CASLNs. It was intriguing that the increment of the charge as a function of the concentration of catanionic surfactant was approximately linear. WGA-Lf-ETP-CASLNs revealed an integral structure with smooth particle contour, displayed a lighter exterior layer of catanionic surfactant, WGA, and Lf and showed a rigid interior region of solid lipids. A variation in the concentration of catanionic surfactant between 5 μM and 15 μM yielded a maximal encapsulation efficiency of ETP ata 7.5 μM of catanionic surfactant. An increase in the concentration of Lf/WGA decreased the grafting efficiency of Lf/WGA. Also, an increase in the weight percentage of ETP decreased its encapsulation efficiency. Moreover, the release rate of ETP from WGA-Lf-ETP-CASLNs reduced with increasing concentration of catanionic surfactant, and WGA-Lf-ETP-CASLNs at 12.5 μM of catanionic surfactant exhibited a feature of sustained release. The order in the viability of HBMECs was ETP-CASLNs ≅ Lf-ETP-CASLNs ≅ WGA-Lf-ETP-CASLNs > ETP. The variation in the transendothelial electrical resistance (TEER) and permeability of propidium iodide (PI) was negligible when the concentration of Lf increased. Furthermore, an increase in the concentration of WGA from 0.2 to 0.6 mg/mL insignificantly altered the TEER and permeability of PI. When the concentration of Lf increased from 2.5 to 7.5 μg/mL and the concentration of WGA increased from 2.5 to 5 μg/mL, the enhancement in the permeability of ETP was minor. However, 10 μg/mL of Lf promoted the permeability of ETP using Lf-ETP-CASLNs, and 5 and 10 μg/mL of WGA could considerably improve the permeability of ETP using WGA-Lf-ETP-CASLNs. The order in the efficacy of inhibiting U87MG cells was WGA-Lf-ETP-CASLNs > Lf-ETP-CASLNs > ETP-CASLNs > ETP. As a result, WGA-Lf-ETP-CASLNs reduced the TEER, enhanced the permeability of PI, induced a minor cytotoxicity to HBMECs, increased the permeability of ETP across the BBB, and improved the antiproliferative efficacy of U87MG cells. The grafting of WGA and Lf is crucial to control the medicinal property of ETP-CASLNs and WGA-Lf-ETP-CASLNs can be promising colloidal carriers in GBM management. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=catanionic%20solid%20lipid%20nanoparticle" title="catanionic solid lipid nanoparticle">catanionic solid lipid nanoparticle</a>, <a href="https://publications.waset.org/abstracts/search?q=etoposide" title=" etoposide"> etoposide</a>, <a href="https://publications.waset.org/abstracts/search?q=glioblastoma%20multiforme" title=" glioblastoma multiforme"> glioblastoma multiforme</a>, <a href="https://publications.waset.org/abstracts/search?q=lactoferrin" title=" lactoferrin"> lactoferrin</a>, <a href="https://publications.waset.org/abstracts/search?q=wheat%20germ%20agglutinin" title=" wheat germ agglutinin"> wheat germ agglutinin</a> </p> <a href="https://publications.waset.org/abstracts/69376/effect-of-wheat-germ-agglutinin-and-lactoferrin-grafted-catanionic-solid-lipid-nanoparticles-on-targeting-delivery-of-etoposide-to-glioblastoma-multiforme" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/69376.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">237</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">4145</span> Estimation of Thermal Conductivity of Nanofluids Using MD-Stochastic Simulation-Based Approach</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Sujoy%20Das">Sujoy Das</a>, <a href="https://publications.waset.org/abstracts/search?q=M.%20M.%20Ghosh"> M. M. Ghosh</a> </p> <p class="card-text"><strong>Abstract:</strong></p> The thermal conductivity of a fluid can be significantly enhanced by dispersing nano-sized particles in it, and the resultant fluid is termed as "nanofluid". A theoretical model for estimating the thermal conductivity of a nanofluid has been proposed here. It is based on the mechanism that evenly dispersed nanoparticles within a nanofluid undergo Brownian motion in course of which the nanoparticles repeatedly collide with the heat source. During each collision a rapid heat transfer occurs owing to the solid-solid contact. Molecular dynamics (MD) simulation of the collision of nanoparticles with the heat source has shown that there is a pulse-like pick up of heat by the nanoparticles within 20-100 ps, the extent of which depends not only on thermal conductivity of the nanoparticles, but also on the elastic and other physical properties of the nanoparticle. After the collision the nanoparticles undergo Brownian motion in the base fluid and release the excess heat to the surrounding base fluid within 2-10 ms. The Brownian motion and associated temperature variation of the nanoparticles have been modeled by stochastic analysis. Repeated occurrence of these events by the suspended nanoparticles significantly contributes to the characteristic thermal conductivity of the nanofluids, which has been estimated by the present model for a ethylene glycol based nanofluid containing Cu-nanoparticles of size ranging from 8 to 20 nm, with Gaussian size distribution. The prediction of the present model has shown a reasonable agreement with the experimental data available in literature. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=brownian%20dynamics" title="brownian dynamics">brownian dynamics</a>, <a href="https://publications.waset.org/abstracts/search?q=molecular%20dynamics" title=" molecular dynamics"> molecular dynamics</a>, <a href="https://publications.waset.org/abstracts/search?q=nanofluid" title=" nanofluid"> nanofluid</a>, <a href="https://publications.waset.org/abstracts/search?q=thermal%20conductivity" title=" thermal conductivity"> thermal conductivity</a> </p> <a href="https://publications.waset.org/abstracts/16894/estimation-of-thermal-conductivity-of-nanofluids-using-md-stochastic-simulation-based-approach" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/16894.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">371</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">4144</span> Optimizing the Effectiveness of Docetaxel with Solid Lipid Nanoparticles: Formulation, Characterization, in Vitro and in Vivo Assessment</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Navid%20Mosallaei">Navid Mosallaei</a>, <a href="https://publications.waset.org/abstracts/search?q=Mahmoud%20Reza%20Jaafari"> Mahmoud Reza Jaafari</a>, <a href="https://publications.waset.org/abstracts/search?q=Mohammad%20Yahya%20Hanafi-Bojd"> Mohammad Yahya Hanafi-Bojd</a>, <a href="https://publications.waset.org/abstracts/search?q=Shiva%20Golmohammadzadeh"> Shiva Golmohammadzadeh</a>, <a href="https://publications.waset.org/abstracts/search?q=Bizhan%20Malaekeh-Nikouei"> Bizhan Malaekeh-Nikouei</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background: Docetaxel (DTX), a potent anticancer drug derived from the European yew tree, is effective against various human cancers by inhibiting microtubule depolymerization. Solid lipid nanoparticles (SLNs) have gained attention as drug carriers for enhancing drug effectiveness and safety. SLNs, submicron-sized lipid-based particles, can passively target tumors through the "enhanced permeability and retention" (EPR) effect, providing stability, drug protection, and controlled release while being biocompatible. Methods: The SLN formulation included biodegradable lipids (Compritol and Precirol), hydrogenated soy phosphatidylcholine (H-SPC) as a lipophilic co-surfactant, and Poloxamer 188 as a non-ionic polymeric stabilizer. Two SLN preparation techniques, probe sonication and microemulsion, were assessed. Characterization encompassed SLNs' morphology, particle size, zeta potential, matrix, and encapsulation efficacy. In-vitro cytotoxicity and cellular uptake studies were conducted using mouse colorectal (C-26) and human malignant melanoma (A-375) cell lines, comparing SLN-DTX with Taxotere®. In-vivo studies evaluated tumor inhibitory efficacy and survival in mice with colorectal (C-26) tumors, comparing SLNDTX withTaxotere®. Results: SLN-DTX demonstrated stability, with an average size of 180 nm and a low polydispersity index (PDI) of 0.2 and encapsulation efficacy of 98.0 ± 0.1%. Differential scanning calorimetry (DSC) suggested amorphous encapsulation of DTX within SLNs. In vitro studies revealed that SLN-DTX exhibited nearly equivalent cytotoxicity to Taxotere®, depending on concentration and exposure time. Cellular uptake studies demonstrated superior intracellular DTX accumulation with SLN-DTX. In a C-26 mouse model, SLN-DTX at 10 mg/kg outperformed Taxotere® at 10 and 20 mg/kg, with no significant differences in body weight changes and a remarkably high survival rate of 60%. Conclusion: This study concludes that SLN-DTX, prepared using the probe sonication, offers stability and enhanced therapeutic effects. It displayed almost same in vitro cytotoxicity to Taxotere® but showed superior cellular uptake. In a mouse model, SLN-DTX effectively inhibited tumor growth, with 10 mg/kg outperforming even 20 mg/kg of Taxotere®, without adverse body weight changes and with higher survival rates. This suggests that SLN-DTX has the potential to reduce adverse effects while maintaining or enhancing docetaxel's therapeutic profile, making it a promising drug delivery strategy suitable for industrialization. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=docetaxel" title="docetaxel">docetaxel</a>, <a href="https://publications.waset.org/abstracts/search?q=Taxotere%C2%AE" title=" Taxotere®"> Taxotere®</a>, <a href="https://publications.waset.org/abstracts/search?q=solid%20lipid%20nanoparticles" title=" solid lipid nanoparticles"> solid lipid nanoparticles</a>, <a href="https://publications.waset.org/abstracts/search?q=enhanced%20permeability%20and%20retention%20effect" title=" enhanced permeability and retention effect"> enhanced permeability and retention effect</a>, <a href="https://publications.waset.org/abstracts/search?q=drug%20delivery" title=" drug delivery"> drug delivery</a>, <a href="https://publications.waset.org/abstracts/search?q=cancer%20chemotherapy" title=" cancer chemotherapy"> cancer chemotherapy</a>, <a href="https://publications.waset.org/abstracts/search?q=cytotoxicity" title=" cytotoxicity"> cytotoxicity</a>, <a href="https://publications.waset.org/abstracts/search?q=cellular%20uptake" title=" cellular uptake"> cellular uptake</a>, <a href="https://publications.waset.org/abstracts/search?q=tumor%20inhibition" title=" tumor inhibition"> tumor inhibition</a> </p> <a href="https://publications.waset.org/abstracts/174266/optimizing-the-effectiveness-of-docetaxel-with-solid-lipid-nanoparticles-formulation-characterization-in-vitro-and-in-vivo-assessment" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/174266.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">82</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">4143</span> Collagen Silver Lipid Nanoparticles as Matrix and Fillers for Cosmeceuticals: An In-Vitro and In-Vivo Study</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Kumari%20Kajal">Kumari Kajal</a>, <a href="https://publications.waset.org/abstracts/search?q=Muthu%20Kumar%20Sampath"> Muthu Kumar Sampath</a>, <a href="https://publications.waset.org/abstracts/search?q=Hare%20Ram%20Singh"> Hare Ram Singh</a> </p> <p class="card-text"><strong>Abstract:</strong></p> In this context, the formulation and characterization of collagen silver lipid nanoparticles (CSLNs) were studied for their capacity to serve as fillers/matrix materials used in cosmeceutical applications. The CSLNs were prepared following a series of studies, such as X-ray diffraction (XRD), field-emission scanning electron microscopy (FESEM) coupled with energy-dispersive X-ray spectroscopy (EDS), Fourier-transform infrared spectroscopy FT-IR; thermogravimetric analysis (TGA); and differential scanning calorimetry (DSC). The studies confirmed the structural integrity of nanoparticles, their cargo and thermal stability. The biological functionality of CSLNs was studied by carrying out in vitro & in vivo studies. The antibacterial effect, hemocompatibility and anti-inflammatory characteristics of these fibers were systematically investigated. The toxicological assays included oral toxicity in mice and aquatic life tests with the fish Danio rerio model. The morphology of the nanoparticles was confirmed using high-resolution transmission electron microscopy (HR-TEM). The report found that CSLNs had strong antimicrobial effects, unmatched hemocompatibility, and low or absent inflammatory reactions, which makes them perfect candidates for cosmeceutical applications. The toxicological evaluations evinced a good safety record without any significant adverse effects in both murine and Danio rerio models. This research reveals the efficient way of CSLNs to the efficacy and safety of dermaceuticals. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=collagen%20silver%20lipid%20nanoparticles%20%28CSLNs%29" title="collagen silver lipid nanoparticles (CSLNs)">collagen silver lipid nanoparticles (CSLNs)</a>, <a href="https://publications.waset.org/abstracts/search?q=cosmeceuticals" title=" cosmeceuticals"> cosmeceuticals</a>, <a href="https://publications.waset.org/abstracts/search?q=antimicrobial%20activity" title=" antimicrobial activity"> antimicrobial activity</a>, <a href="https://publications.waset.org/abstracts/search?q=hemocompatibility" title=" hemocompatibility"> hemocompatibility</a>, <a href="https://publications.waset.org/abstracts/search?q=in%20vitro%20assessment" title=" in vitro assessment"> in vitro assessment</a>, <a href="https://publications.waset.org/abstracts/search?q=in%20vivo%20assessment." title=" in vivo assessment."> in vivo assessment.</a> </p> <a href="https://publications.waset.org/abstracts/193215/collagen-silver-lipid-nanoparticles-as-matrix-and-fillers-for-cosmeceuticals-an-in-vitro-and-in-vivo-study" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/193215.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">15</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">4142</span> Synthesis of Nickel Oxide Nanoparticles in Presence of Sodium Dodecyl Sulphate</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Fereshteh%20Chekin">Fereshteh Chekin</a>, <a href="https://publications.waset.org/abstracts/search?q=Sepideh%20Sadeghi"> Sepideh Sadeghi </a> </p> <p class="card-text"><strong>Abstract:</strong></p> Nickel nanoparticles have attracted much attention because of applications in catalysis, medical diagnostics and magnetic applications. In this work, we reported a simple and low-cost procedure to synthesize nickel oxide nanoparticles (NiO-NPs) by using sodium dodecyl sulphate (SDS) and gelatin as stabilizer. The synthesized NiO-NPs were characterized by a variety of means such as transmission electron microscope (TEM), powder X-ray diffraction (XRD), scanning electron microscope (SEM) and UV-vis spectroscopy. The results show that the NiO nanoparticles with high crystalline can be obtained using this simple method. The grain size measured by TEM was 16 in presence of SDS, which agrees well with the XRD data. SDS plays an important role in the formation of the NiO nanoparticles. Moreover, the NiO nanoparticles have been used as a solid phase catalyst for the decomposition of hydrazine hydrate at room temperatures. The decomposition process has been monitored by UV–vis analysis. The present study showed that nanoparticles are not poisoned after their repeated use in decomposition of hydrazine. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=nickel%20oxide%20nanoparticles" title="nickel oxide nanoparticles">nickel oxide nanoparticles</a>, <a href="https://publications.waset.org/abstracts/search?q=sodium%20dodecyl%20sulphate" title=" sodium dodecyl sulphate"> sodium dodecyl sulphate</a>, <a href="https://publications.waset.org/abstracts/search?q=synthesis" title=" synthesis"> synthesis</a>, <a href="https://publications.waset.org/abstracts/search?q=stabilizer" title=" stabilizer"> stabilizer</a> </p> <a href="https://publications.waset.org/abstracts/14906/synthesis-of-nickel-oxide-nanoparticles-in-presence-of-sodium-dodecyl-sulphate" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/14906.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">486</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">4141</span> Spinach Lipid Extract as an Alternative Flow Aid for Fat Suspensions</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Nizaha%20Juhaida%20Mohamad">Nizaha Juhaida Mohamad</a>, <a href="https://publications.waset.org/abstracts/search?q=David%20Gray"> David Gray</a>, <a href="https://publications.waset.org/abstracts/search?q=Bettina%20Wolf"> Bettina Wolf</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Chocolate is a material composite with a high fraction of solid particles dispersed in a fat phase largely composed of cocoa butter. Viscosity properties of chocolate can be manipulated by the amount of fat - increased levels of fat lead to lower viscosity. However, a high content of cocoa butter can increase the cost of the chocolate and instead surfactants are used to manipulate viscosity behaviour. Most commonly, lecithin and polyglycerol polyricinoleate (PGPR) are used. Lecithin is a natural lipid emulsifier which is based on phospholipids while PGPR is a chemically produced emulsifier which based on the long continuous chain of ricinoleic acid. Lecithin and PGPR act to lower the viscosity and yield stress, respectively. Recently, natural lipid emulsifiers based on galactolipid as the functional ingredient have become of interest. Spinach lipid is found to have a high amount of galactolipid, specifically MGDG and DGDG. The aim of this research is to explore the influence of spinach lipid in comparison with PGPR and lecithin on the rheological properties of sugar/oil suspensions which serve as chocolate model system. For that purpose, icing sugar was dispersed from 40%, 45% and 50% (w/w) in oil which has spinach lipid at concentrations from 0.1 – 0.7% (w/w). Based on viscosity at 40 s-1 and yield value reported as shear stress measured at 5 s-1, it was found that spinach lipid shows viscosity reducing and yield stress lowering effects comparable to lecithin and PGPR, respectively. This characteristic of spinach lipid demonstrates great potential for it to act as single natural lipid emulsifier in chocolate. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=chocolate%20viscosity" title="chocolate viscosity">chocolate viscosity</a>, <a href="https://publications.waset.org/abstracts/search?q=lecithin" title=" lecithin"> lecithin</a>, <a href="https://publications.waset.org/abstracts/search?q=polyglycerol%20polyricinoleate%20%28PGPR%29" title=" polyglycerol polyricinoleate (PGPR)"> polyglycerol polyricinoleate (PGPR)</a>, <a href="https://publications.waset.org/abstracts/search?q=spinach%20lipid" title=" spinach lipid"> spinach lipid</a> </p> <a href="https://publications.waset.org/abstracts/46928/spinach-lipid-extract-as-an-alternative-flow-aid-for-fat-suspensions" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/46928.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">248</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">4140</span> Fabrication of Ligand Coated Lipid-Based Nanoparticles for Synergistic Treatment of Autoimmune Disease</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Asiya%20Mahtab">Asiya Mahtab</a>, <a href="https://publications.waset.org/abstracts/search?q=Sushama%20Talegaonkar"> Sushama Talegaonkar </a> </p> <p class="card-text"><strong>Abstract:</strong></p> The research is aimed at developing targeted lipid-based nanocarrier systems of chondroitin sulfate (CS) to deliver an antirheumatic drug to the inflammatory site in arthritic paw. Lipid-based nanoparticle (TEF-lipo) was prepared by using a thin-film hydration method. The coating of prepared drug-loaded nanoparticles was done by the ionic interaction mechanism. TEF-lipo and CS-coated lipid nanoparticle (CS-lipo) were characterized for mean droplet size, zeta potential, and surface morphology. TEF-lipo and CS-lipo were further subjected to in vitro cell line studies on RAW 264.7 murine macrophage, U937, and MG 63 cell lines. The pharmacodynamic study was performed to establish the effectiveness of the prepared lipid-based conventional and targeted nanoparticles in comparison to pure drugs. Droplet size and zeta potential of TEF-lipo were found to be 128. 92 ± 5.42 nm and +12.6 ± 1.2 mV. It was observed that after the coating of TEF-lipo with CS, particle size increased to 155.6± 2.12 nm and zeta potential changed to -10.2± 1.4mV. Transmission electron microscopic analysis revealed that the nanovesicles were uniformly dispersed and detached from each other. Formulations followed sustained release pattern up to 24 h. Results of cell line studies ind icated that CS-lipo formulation showed the highest cytotoxic potential, thereby proving its enhanced ability to kill the RAW 264.7 murine macrophage and U937 cells when compared with other formulations. It is clear from our in vivo pharmacodynamic results that targeted nanocarriers had a higher inhibitory effect on arthritis progression than nontargeted nanocarriers or free drugs. Results demonstrate that this approach will provide effective treatment for rheumatoid arthritis, and CS served as a potential prophylactic against the advancement of cartilage degeneration. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=adjuvant%20induced%20arthritis" title="adjuvant induced arthritis">adjuvant induced arthritis</a>, <a href="https://publications.waset.org/abstracts/search?q=chondroitin%20sulfate" title=" chondroitin sulfate"> chondroitin sulfate</a>, <a href="https://publications.waset.org/abstracts/search?q=rheumatoid%20arthritis" title=" rheumatoid arthritis"> rheumatoid arthritis</a>, <a href="https://publications.waset.org/abstracts/search?q=teriflunomide" title=" teriflunomide"> teriflunomide</a> </p> <a href="https://publications.waset.org/abstracts/116801/fabrication-of-ligand-coated-lipid-based-nanoparticles-for-synergistic-treatment-of-autoimmune-disease" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/116801.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">136</span> </span> </div> </div> <ul class="pagination"> <li class="page-item disabled"><span class="page-link">&lsaquo;</span></li> <li class="page-item active"><span class="page-link">1</span></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=solid%20lipid%20nanoparticles&page=2">2</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=solid%20lipid%20nanoparticles&page=3">3</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=solid%20lipid%20nanoparticles&page=4">4</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=solid%20lipid%20nanoparticles&page=5">5</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=solid%20lipid%20nanoparticles&page=6">6</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=solid%20lipid%20nanoparticles&page=7">7</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=solid%20lipid%20nanoparticles&page=8">8</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=solid%20lipid%20nanoparticles&page=9">9</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=solid%20lipid%20nanoparticles&page=10">10</a></li> <li class="page-item disabled"><span class="page-link">...</span></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=solid%20lipid%20nanoparticles&page=138">138</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=solid%20lipid%20nanoparticles&page=139">139</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=solid%20lipid%20nanoparticles&page=2" rel="next">&rsaquo;</a></li> </ul> </div> </main> <footer> <div id="infolinks" class="pt-3 pb-2"> <div class="container"> <div style="background-color:#f5f5f5;" class="p-3"> <div class="row"> <div class="col-md-2"> <ul class="list-unstyled"> About <li><a href="https://waset.org/page/support">About Us</a></li> <li><a href="https://waset.org/page/support#legal-information">Legal</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/WASET-16th-foundational-anniversary.pdf">WASET celebrates its 16th foundational anniversary</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Account <li><a href="https://waset.org/profile">My Account</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Explore <li><a href="https://waset.org/disciplines">Disciplines</a></li> <li><a href="https://waset.org/conferences">Conferences</a></li> <li><a href="https://waset.org/conference-programs">Conference Program</a></li> <li><a href="https://waset.org/committees">Committees</a></li> <li><a href="https://publications.waset.org">Publications</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Research <li><a href="https://publications.waset.org/abstracts">Abstracts</a></li> <li><a href="https://publications.waset.org">Periodicals</a></li> <li><a href="https://publications.waset.org/archive">Archive</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Open Science <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Open-Science-Philosophy.pdf">Open Science Philosophy</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Open-Science-Award.pdf">Open Science Award</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Open-Society-Open-Science-and-Open-Innovation.pdf">Open Innovation</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Postdoctoral-Fellowship-Award.pdf">Postdoctoral Fellowship Award</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Scholarly-Research-Review.pdf">Scholarly Research Review</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Support <li><a href="https://waset.org/page/support">Support</a></li> <li><a href="https://waset.org/profile/messages/create">Contact Us</a></li> <li><a href="https://waset.org/profile/messages/create">Report Abuse</a></li> </ul> </div> </div> </div> </div> </div> <div class="container text-center"> <hr style="margin-top:0;margin-bottom:.3rem;"> <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank" class="text-muted small">Creative Commons Attribution 4.0 International License</a> <div id="copy" class="mt-2">© 2024 World Academy of Science, Engineering and Technology</div> </div> </footer> <a href="javascript:" id="return-to-top"><i class="fas fa-arrow-up"></i></a> <div class="modal" id="modal-template"> <div class="modal-dialog"> <div class="modal-content"> <div class="row m-0 mt-1"> <div class="col-md-12"> <button type="button" class="close" data-dismiss="modal" aria-label="Close"><span aria-hidden="true">×</span></button> </div> </div> <div class="modal-body"></div> </div> </div> </div> <script src="https://cdn.waset.org/static/plugins/jquery-3.3.1.min.js"></script> <script src="https://cdn.waset.org/static/plugins/bootstrap-4.2.1/js/bootstrap.bundle.min.js"></script> <script src="https://cdn.waset.org/static/js/site.js?v=150220211556"></script> <script> jQuery(document).ready(function() { /*jQuery.get("https://publications.waset.org/xhr/user-menu", function (response) { jQuery('#mainNavMenu').append(response); });*/ jQuery.get({ url: "https://publications.waset.org/xhr/user-menu", cache: false }).then(function(response){ jQuery('#mainNavMenu').append(response); }); }); </script> </body> </html>